Aarhus University Seal / Aarhus Universitets segl

Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Marjolein De Bruin-Weller, National Expertise Center for Eczema, Utrecht
  • ,
  • Tilo Biedermann, Technical University of Munich
  • ,
  • Robert Bissonnette, Innovaderm Research, Montreal, QC, Canada.
  • ,
  • Mette Deleuran
  • Peter Foley, St. Vincent's Hospital Melbourne, Skin Health Institute, Melbourne
  • ,
  • Giampiero Girolomoni, University of Verona
  • ,
  • Jana Hercogová, Charles University, Na Bulovce Hospital
  • ,
  • Chih-Ho Hong, University of British Columbia
  • ,
  • Norito Katoh, Kyoto Prefectural University of Medicine
  • ,
  • Andrew E Pink, Guy's and St Thomas' NHS Foundation Trust, Kings College, London
  • ,
  • Marie-Aleth Richard, Aix-Marseille University, La Timone Hospital University, Marseille, France., Assistance Publique Hôpitaux de Marseille
  • ,
  • Stephen Shumack, Royal North Shore Hospital
  • ,
  • Juan F Silvestre, Hospital General Universitario de Alicante
  • ,
  • Stephan Weidinger, University Hospital Schleswig-Holstein

Currently no treat-to-target framework to guide systemic treatment in adults with moderate-to-severe atopic dermatitis exists. We sought to reach international consensus through an eDelphi process on a core set of recommendations for such an approach. Recommendations were developed by an international Steering Committee, spanning 3 areas (Guiding Principles, Decision Making, and Outcome Thresholds) and 2 specific time-points; an initial acceptable target at 3 months and an optimal target at 6 months, each based on improvements in patient global assessment plus at least one specific outcome domain. These treat-to-target- orientated recommendations were evaluated by an extended international panel of physicians, nurses and patients. Proposed recommendations were rated using a 9-point Likert scale; for each recommendation, consensus agreement was reached if ≥ 75% of all respondents rated agreement as ≥ 7. Consensus on 16 core recommendations was reached over 2 eDelphi rounds. These provide a framework for shared decision-making on systemic treatment continuation, modification, or discontinuation.

OriginalsprogEngelsk
Artikelnummeradv00402
TidsskriftActa Dermato-Venereologica
Vol/bind101
Nummer2
Antal sider7
ISSN0001-5555
DOI
StatusUdgivet - feb. 2021

Se relationer på Aarhus Universitet Citationsformater

ID: 213753928